Form 8-K - Current report:
SEC Accession No. 0001564590-18-005402
Filing Date
2018-03-13
Accepted
2018-03-13 07:00:24
Documents
3
Period of Report
2018-03-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 2017 YE 8-K agle-8k_20180313.htm 8-K 34766
2 EX-99.1 agle-ex991_6.htm EX-99.1 245311
3 GRAPHIC g201803122336316963310.jpg GRAPHIC 3061
  Complete submission text file 0001564590-18-005402.txt   285651
Mailing Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746
Business Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 18685207
SIC: 2834 Pharmaceutical Preparations